139 related articles for article (PubMed ID: 30559310)
21. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
22. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
Lee BH; Williams IR; Anastasiadou E; Boulton CL; Joseph SW; Amaral SM; Curley DP; Duclos N; Huntly BJ; Fabbro D; Griffin JD; Gilliland DG
Oncogene; 2005 Nov; 24(53):7882-92. PubMed ID: 16116483
[TBL] [Abstract][Full Text] [Related]
23. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
24. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia.
Lin P; Jones D; Medeiros LJ; Chen W; Vega-Vazquez F; Luthra R
Am J Clin Pathol; 2006 Oct; 126(4):530-3. PubMed ID: 16938665
[TBL] [Abstract][Full Text] [Related]
25. Quizartinib, the next FLT3 inhibitor.
Cortes J
Clin Adv Hematol Oncol; 2023 May; 21(5):240-243. PubMed ID: 37145493
[No Abstract] [Full Text] [Related]
26. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
[TBL] [Abstract][Full Text] [Related]
27. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
Smith CC; Zhang C; Lin KC; Lasater EA; Zhang Y; Massi E; Damon LE; Pendleton M; Bashir A; Sebra R; Perl A; Kasarskis A; Shellooe R; Tsang G; Carias H; Powell B; Burton EA; Matusow B; Zhang J; Spevak W; Ibrahim PN; Le MH; Hsu HH; Habets G; West BL; Bollag G; Shah NP
Cancer Discov; 2015 Jun; 5(6):668-79. PubMed ID: 25847190
[TBL] [Abstract][Full Text] [Related]
28. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
29. Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion.
Munthe-Kaas MC; Forthun RB; Brendehaug A; Eek AK; Høysæter T; Osnes LTN; Prescott T; Spetalen S; Hovland R
J Pediatr Hematol Oncol; 2021 May; 43(4):e508-e511. PubMed ID: 32852395
[TBL] [Abstract][Full Text] [Related]
30. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
[TBL] [Abstract][Full Text] [Related]
31. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
Ritchie KA; Aprikyan AA; Bowen-Pope DF; Norby-Slycord CJ; Conyers S; Bartelmez S; Sitnicka EH; Hickstein DD
Leukemia; 1999 Nov; 13(11):1790-803. PubMed ID: 10557054
[TBL] [Abstract][Full Text] [Related]
32. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.
Gratias EJ; Liu YL; Meleth S; Castleberry RP; Emanuel PD
Pediatr Blood Cancer; 2005 Feb; 44(2):142-6. PubMed ID: 15390271
[TBL] [Abstract][Full Text] [Related]
33. Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
von Bubnoff N; Rummelt C; Menzel H; Sigl M; Peschel C; Duyster J
Leukemia; 2010 Aug; 24(8):1523-5. PubMed ID: 20520641
[No Abstract] [Full Text] [Related]
34. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
Yang N; Gu Z; Liu Z; Huang W; Wang S; Wang L; Gao C
Anticancer Agents Med Chem; 2018; 18(10):1489-1494. PubMed ID: 29521250
[TBL] [Abstract][Full Text] [Related]
35. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases.
Saft L; Kvasnicka HM; Boudova L; Gianelli U; Lazzi S; Rozman M
Histopathology; 2023 Dec; 83(6):829-849. PubMed ID: 37551450
[TBL] [Abstract][Full Text] [Related]
36. The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib.
Friedman R
Proteins; 2017 Nov; 85(11):2143-2152. PubMed ID: 28799176
[TBL] [Abstract][Full Text] [Related]
37.
Zhang H; Wang X; Li S; Wang X; Lu X; Li M; Wang H; Liu Y; Pang H; Zhang L
Dis Markers; 2021; 2021():9932837. PubMed ID: 34194582
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
Auclair D; Miller D; Yatsula V; Pickett W; Carter C; Chang Y; Zhang X; Wilkie D; Burd A; Shi H; Rocks S; Gedrich R; Abriola L; Vasavada H; Lynch M; Dumas J; Trail PA; Wilhelm SM
Leukemia; 2007 Mar; 21(3):439-45. PubMed ID: 17205056
[TBL] [Abstract][Full Text] [Related]
39. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
[TBL] [Abstract][Full Text] [Related]
40. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
